sorry I am driving and my brain is a little spongy this morning with the bad news, so I forget which Statin worked best. However, still holding out hope that the sub data shows very strong results for one over the other, to a level that cannot be ignored for patient benefits. It has been asked if a company can proceed to an approval process with failed primary end points in the total population, however sub data pointing in “a” direction that cannot be ignored for patient benefit?